Antibiotic-induced collateral damage to the microbiota and associated infections.
Journal
Nature reviews. Microbiology
ISSN: 1740-1534
Titre abrégé: Nat Rev Microbiol
Pays: England
ID NLM: 101190261
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
28
06
2023
medline:
13
11
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
ppublish
Résumé
Antibiotics have transformed medicine, saving millions of lives since they were first used to treat a bacterial infection. However, antibiotics administered to target a specific pathogen can also cause collateral damage to the patient's resident microbial population. These drugs can suppress the growth of commensal species which provide protection against colonization by foreign pathogens, leading to an increased risk of subsequent infection. At the same time, a patient's microbiota can harbour potential pathogens and, hence, be a source of infection. Antibiotic-induced selection pressure can cause overgrowth of resistant pathogens pre-existing in the patient's microbiota, leading to hard-to-treat superinfections. In this Review, we explore our current understanding of how antibiotic therapy can facilitate subsequent infections due to both loss of colonization resistance and overgrowth of resistant microorganisms, and how these processes are often interlinked. We discuss both well-known and currently overlooked examples of antibiotic-associated infections at various body sites from various pathogens. Finally, we describe ongoing and new strategies to overcome the collateral damage caused by antibiotics and to limit the risk of antibiotic-associated infections.
Identifiants
pubmed: 37542123
doi: 10.1038/s41579-023-00936-9
pii: 10.1038/s41579-023-00936-9
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
789-804Informations de copyright
© 2023. Springer Nature Limited.
Références
Browne, A. J. et al. Global antibiotic consumption and usage in humans, 2000–18: a spatial modelling study. Lancet Planet. Health 5, e893–e904 (2021).
pubmed: 34774223
pmcid: 8654683
doi: 10.1016/S2542-5196(21)00280-1
Stewardson, A. J., Huttner, B. & Harbarth, S. At least it won’t hurt: the personal risks of antibiotic exposure. Curr. Opin. Pharmacol. 11, 446–452 (2011).
pubmed: 21775205
doi: 10.1016/j.coph.2011.06.011
Blaser, M. J. Antibiotic use and its consequences for the normal microbiome. Science 352, 544–545 (2016).
pubmed: 27126037
pmcid: 4939477
doi: 10.1126/science.aad9358
Hogenauer, C., Hammer, H. F., Krejs, G. J. & Reisinger, E. C. Mechanisms and management of antibiotic‐associated diarrhea. Clin. Infect. Dis. 27, 702–710 (1998).
pubmed: 9798020
doi: 10.1086/514958
McFarland, L. V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig. Dis. Basel Switz. 16, 292–307 (1998).
doi: 10.1159/000016879
Caballero-Flores, G., Pickard, J. M. & Núñez, G. Microbiota-mediated colonization resistance: mechanisms and regulation. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-022-00833-7 (2022). A comprehensive review on the mechanisms and regulation of colonization resistance.
doi: 10.1038/s41579-022-00833-7
pubmed: 36539611
Sender, R., Fuchs, S. & Milo, R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).
pubmed: 27541692
pmcid: 4991899
doi: 10.1371/journal.pbio.1002533
Faith, J. J. et al. The long-term stability of the human gut microbiota. Science 341, 1237439 (2013).
pubmed: 23828941
pmcid: 3791589
doi: 10.1126/science.1237439
Wypych, T. P. & Marsland, B. J. Antibiotics as instigators of microbial dysbiosis: implications for asthma and allergy. Trends Immunol. 39, 697–711 (2018).
pubmed: 29655522
doi: 10.1016/j.it.2018.02.008
Yuan, J. et al. Long-term use of antibiotics and risk of type 2 diabetes in women: a prospective cohort study. Int. J. Epidemiol. 49, 1572–1581 (2020).
pubmed: 32893302
pmcid: 7746404
doi: 10.1093/ije/dyaa122
Park, S. J. et al. Association between antibiotics use and diabetes incidence in a nationally representative retrospective cohort among Koreans. Sci. Rep. 11, 21681 (2021).
pubmed: 34737360
pmcid: 8568925
doi: 10.1038/s41598-021-01125-5
Zhou, W. et al. Longitudinal multi-omics of host–microbe dynamics in prediabetes. Nature 569, 663–671 (2019).
pubmed: 31142858
pmcid: 6666404
doi: 10.1038/s41586-019-1236-x
Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).
pubmed: 27974040
doi: 10.1056/NEJMra1600266
Trasande, L. et al. Infant antibiotic exposures and early-life body mass. Int. J. Obes. 37, 16–23 (2013).
doi: 10.1038/ijo.2012.132
Teng, C., Reveles, K. R., Obodozie-Ofoegbu, O. O. & Frei, C. R. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system. Int. J. Med. Sci. 16, 630–635 (2019).
pubmed: 31217729
pmcid: 6566741
doi: 10.7150/ijms.30739
Högenauer, C. et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N. Engl. J. Med. 355, 2418–2426 (2006).
pubmed: 17151365
doi: 10.1056/NEJMoa054765
Shukla, A. & Sobel, J. D. Vulvovaginitis caused by Candida species following antibiotic exposure. Curr. Infect. Dis. Rep. 21, 44 (2019).
pubmed: 31707496
doi: 10.1007/s11908-019-0700-y
Ben-Ami, R. et al. Antibiotic exposure as a risk factor for fluconazole-resistant Candida bloodstream infection. Antimicrob. Agents Chemother. 56, 2518–2523 (2012).
pubmed: 22314534
pmcid: 3346668
doi: 10.1128/AAC.05947-11
Ichinohe, T. et al. Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc. Natl Acad. Sci. USA 108, 5354–5359 (2011).
pubmed: 21402903
pmcid: 3069176
doi: 10.1073/pnas.1019378108
Blair, J. M. A., Webber, M. A., Baylay, A. J., Ogbolu, D. O. & Piddock, L. J. V. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 13, 42–51 (2014).
pubmed: 25435309
doi: 10.1038/nrmicro3380
Bush, K. et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9, 894–896 (2011).
pubmed: 22048738
pmcid: 4206945
doi: 10.1038/nrmicro2693
Yassour, M. et al. Natural history of the infant gut microbiome and impact of antibiotic treatment on bacterial strain diversity and stability. Sci. Transl. Med. 8, 343ra81 (2016). This longitudinal study of the infant gut microbiome observed transient blooms of specific species and resistance levels during antibiotic treatment.
pubmed: 27306663
pmcid: 5032909
doi: 10.1126/scitranslmed.aad0917
Stecher, B., Maier, L. & Hardt, W.-D. ‘Blooming’ in the gut: how dysbiosis might contribute to pathogen evolution. Nat. Rev. Microbiol. 11, 277–284 (2013).
pubmed: 23474681
doi: 10.1038/nrmicro2989
Buffie, C. G. et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect. Immun. 80, 62–73 (2012).
pubmed: 22006564
pmcid: 3255689
doi: 10.1128/IAI.05496-11
Shen, Z. et al. Emerging carriage of NDM-5 and MCR-1 in Escherichia coli from healthy people in multiple regions in China: a cross sectional observational study. eClinicalMedicine 6, 11–20 (2018).
pubmed: 31193653
pmcid: 6537561
doi: 10.1016/j.eclinm.2018.11.003
van Hattem, J. M. et al. Prolonged carriage and potential onward transmission of carbapenemase-producing Enterobacteriaceae in Dutch travelers. Future Microbiol. 11, 857–864 (2016).
pubmed: 27357522
doi: 10.2217/fmb.16.18
Hu, Y. et al. Metagenome-wide analysis of antibiotic resistance genes in a large cohort of human gut microbiota. Nat. Commun. 4, 2151 (2013).
pubmed: 23877117
doi: 10.1038/ncomms3151
Group, B. M. J. P. Superinfections during antibiotic treatment. Br. Med. J. 1, 537–538 (1952).
doi: 10.1136/bmj.1.4757.537
Ramirez, J. et al. Antibiotics as major disruptors of gut microbiota. Front. Cell. Infect. Microbiol. 10, 572912 (2020).
pubmed: 33330122
pmcid: 7732679
doi: 10.3389/fcimb.2020.572912
Sullivan, Å. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect. Dis. 1, 101–114 (2001). A review of the drug-specific effects of antibiotic on the microbiota, including extra-intestinal microbiota sites.
pubmed: 11871461
doi: 10.1016/S1473-3099(01)00066-4
Yang, L. et al. The varying effects of antibiotics on gut microbiota. AMB Express 11, 116 (2021).
pubmed: 34398323
pmcid: 8368853
doi: 10.1186/s13568-021-01274-w
Maier, L. et al. Unravelling the collateral damage of antibiotics on gut bacteria. Nature 599, 120–124 (2021). This study comprehensively screened gut commensals to identify drug combinations active against pathogens but that minimize collateral damage against other species.
pubmed: 34646011
pmcid: 7612847
doi: 10.1038/s41586-021-03986-2
Kelly, S. A., Rodgers, A. M., O’Brien, S. C., Donnelly, R. F. & Gilmore, B. F. Gut check time: antibiotic delivery strategies to reduce antimicrobial resistance. Trends Biotechnol. 38, 447–462 (2020).
pubmed: 31757410
doi: 10.1016/j.tibtech.2019.10.008
Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108, 4554–4561 (2011). This study highlights the differences between individuals in the microbiota response and recovery to antibiotics.
pubmed: 20847294
doi: 10.1073/pnas.1000087107
Jeffery, I. B., Lynch, D. B. & O’Toole, P. W. Composition and temporal stability of the gut microbiota in older persons. ISME J. 10, 170–182 (2016).
pubmed: 26090993
doi: 10.1038/ismej.2015.88
Zimmermann, M., Patil, K. R., Typas, A. & Maier, L. Towards a mechanistic understanding of reciprocal drug–microbiome interactions. Mol. Syst. Biol. 17, e10116 (2021).
pubmed: 33734582
pmcid: 7970330
doi: 10.15252/msb.202010116
Gjonbalaj, M. et al. Antibiotic degradation by commensal microbes shields pathogens. Infect. Immun. 88, e00012–e00020 (2020).
pubmed: 31964746
pmcid: 7093146
doi: 10.1128/IAI.00012-20
Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).
pubmed: 24679531
pmcid: 4056765
doi: 10.1016/j.cell.2014.03.011
Byrd, A. L., Belkaid, Y. & Segre, J. A. The human skin microbiome. Nat. Rev. Microbiol. 16, 143–155 (2018).
pubmed: 29332945
doi: 10.1038/nrmicro.2017.157
Elvers, K. T. et al. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open 10, e035677 (2020).
pubmed: 32958481
pmcid: 7507860
doi: 10.1136/bmjopen-2019-035677
Zimmermann, P. & Curtis, N. The effect of antibiotics on the composition of the intestinal microbiota — a systematic review. J. Infect. 79, 471–489 (2019).
pubmed: 31629863
doi: 10.1016/j.jinf.2019.10.008
Levison, M. E. & Levison, J. H. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect. Dis. Clin. North. Am. 23, 791–815 (2009).
pubmed: 19909885
pmcid: 3675903
doi: 10.1016/j.idc.2009.06.008
Levy, R. M., Huang, E. Y., Roling, D., Leyden, J. J. & Margolis, D. J. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch. Dermatol. 139, 467–471 (2003).
pubmed: 12707094
doi: 10.1001/archderm.139.4.467
Kim, S., Covington, A. & Pamer, E. G. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunol. Rev. 279, 90–105 (2017).
pubmed: 28856737
pmcid: 6026851
doi: 10.1111/imr.12563
Kelly, S. A. et al. Antibiotic therapy and the gut microbiome: investigating the effect of delivery route on gut pathogens. ACS Infect. Dis. 7, 1283–1296 (2021).
pubmed: 33843198
doi: 10.1021/acsinfecdis.1c00081
Zhang, L., Huang, Y., Zhou, Y., Buckley, T. & Wang, H. H. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. Antimicrob. Agents Chemother. 57, 3659–3666 (2013). A comparison of oral and intravenous antibiotic administration on the spread of antibiotic resistance in the mouse intestine.
pubmed: 23689712
pmcid: 3719697
doi: 10.1128/AAC.00670-13
Finegold, S. M. Anaerobic infections in humans: an overview. Anaerobe 1, 3–9 (1995).
pubmed: 16887500
doi: 10.1016/S1075-9964(95)80340-8
Eckburg, P. B. et al. Diversity of the human intestinal microbial flora. Science 308, 1635–1638 (2005).
pubmed: 15831718
pmcid: 1395357
doi: 10.1126/science.1110591
Donskey, C. J. et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343, 1925–1932 (2000). This study of patients colonized with vancomycin-resistant enterococci showed overgrowth in the intestine during treatment with various anti-anaerobic antibiotics.
pubmed: 11136263
pmcid: 4370337
doi: 10.1056/NEJM200012283432604
Brook, I., Wexler, H. M. & Goldstein, E. J. C. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin. Microbiol. Rev. 26, 526–546 (2013).
pubmed: 23824372
pmcid: 3719496
doi: 10.1128/CMR.00086-12
Taur, Y. et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin. Infect. Dis. 55, 905–914 (2012). Intestinal domination by various bacteria is associated with subsequent bacteraemia in patients undergoing haematopoietic stem cell transplantation.
pubmed: 22718773
pmcid: 3657523
doi: 10.1093/cid/cis580
Young, V. B. & Schmidt, T. M. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J. Clin. Microbiol. 42, 1203–1206 (2004).
pubmed: 15004076
pmcid: 356823
doi: 10.1128/JCM.42.3.1203-1206.2004
Wiström, J. et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J. Antimicrob. Chemother. 47, 43–50 (2001).
pubmed: 11152430
doi: 10.1093/jac/47.1.43
Ma, H. et al. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. Infect. Drug. Resist. 12, 1047–1054 (2019).
pubmed: 31118710
pmcid: 6503325
doi: 10.2147/IDR.S194715
Rashidi, A. et al. Gut microbiota response to antibiotics is personalized and depends on baseline microbiota. Microbiome 9, 211 (2021).
pubmed: 34702350
pmcid: 8549152
doi: 10.1186/s40168-021-01170-2
Arvidsson, A., Leijd, B., Nord, C. E. & Angelin, B. Interindividual variability in biliary excretion of ceftriaxone: effects on biliary lipid metabolism and on intestinal microflora. Eur. J. Clin. Invest. 18, 261–266 (1988).
pubmed: 3138129
doi: 10.1111/j.1365-2362.1988.tb01256.x
Coyte, K. Z., Schluter, J. & Foster, K. R. The ecology of the microbiome: networks, competition, and stability. Science 350, 663–666 (2015).
pubmed: 26542567
doi: 10.1126/science.aad2602
Dethlefsen, L., Huse, S., Sogin, M. L. & Relman, D. A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6, e280 (2008).
pubmed: 19018661
pmcid: 2586385
doi: 10.1371/journal.pbio.0060280
Anthony, W. E. et al. Acute and persistent effects of commonly used antibiotics on the gut microbiome and resistome in healthy adults. Cell Rep. 39, 110649 (2022). This study shows short- and long-term effects of antibiotics on the gut microbiota of healthy volunteers.
pubmed: 35417701
pmcid: 9066705
doi: 10.1016/j.celrep.2022.110649
Yee, A. L. et al. Longitudinal microbiome composition and stability correlate with increased weight and length of very-low-birth-weight infants. mSystems 4, e00229-18 (2019).
pubmed: 30834328
pmcid: 6392092
doi: 10.1128/mSystems.00229-18
Sorg, R. A. et al. Collective resistance in microbial communities by intracellular antibiotic deactivation. PLoS Biol. 14, e2000631 (2016).
pubmed: 28027306
pmcid: 5189934
doi: 10.1371/journal.pbio.2000631
Cubillos-Ruiz, A. et al. An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis. Nat. Biomed. Eng. 6, 910–921 (2022).
pubmed: 35411114
doi: 10.1038/s41551-022-00871-9
Sun, J. et al. Environmental remodeling of human gut microbiota and antibiotic resistome in livestock farms. Nat. Commun. 11, 1427 (2020).
pubmed: 32188862
pmcid: 7080799
doi: 10.1038/s41467-020-15222-y
Foster, K. R., Schluter, J., Coyte, K. Z. & Rakoff-Nahoum, S. The evolution of the host microbiome as an ecosystem on a leash. Nature 548, 43–51 (2017).
pubmed: 28770836
pmcid: 5749636
doi: 10.1038/nature23292
Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125–1136.e8 (2016).
pubmed: 27814509
pmcid: 5131922
doi: 10.1016/j.cell.2016.10.020
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
pubmed: 29555994
pmcid: 6108420
doi: 10.1038/nature25979
Montandon, S. A. & Jornayvaz, F. R. Effects of antidiabetic drugs on gut microbiota composition. Genes 8, 250 (2017).
pubmed: 28973971
pmcid: 5664100
doi: 10.3390/genes8100250
Le Bastard, Q. et al. Systematic review: human gut dysbiosis induced by non-antibiotic prescription medications. Aliment. Pharmacol. Ther. 47, 332–345 (2018).
pubmed: 29205415
doi: 10.1111/apt.14451
Kwok, C. S. et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am. J. Gastroenterol. 107, 1011–1019 (2012).
pubmed: 22525304
doi: 10.1038/ajg.2012.108
Trifan, A. et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection: systematic review and meta-analysis. World J. Gastroenterol. 23, 6500–6515 (2017).
pubmed: 29085200
pmcid: 5643276
doi: 10.3748/wjg.v23.i35.6500
Caballero-Flores, G., Pickard, J. M., Fukuda, S., Inohara, N. & Núñez, G. An enteric pathogen subverts colonization resistance by evading competition for amino acids in the gut. Cell Host Microbe 28, 526–533.e5 (2020).
pubmed: 32726577
pmcid: 7554178
doi: 10.1016/j.chom.2020.06.018
Theriot, C. M. et al. Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. Nat. Commun. 5, 3114 (2014).
pubmed: 24445449
doi: 10.1038/ncomms4114
Sassone-Corsi, M. et al. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nature 540, 280–283 (2016).
pubmed: 27798599
pmcid: 5145735
doi: 10.1038/nature20557
Buffie, C. G. & Pamer, E. G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 13, 790–801 (2013).
pubmed: 24096337
pmcid: 4194195
doi: 10.1038/nri3535
Ivanov, I. I. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349 (2008).
pubmed: 18854238
pmcid: 2597589
doi: 10.1016/j.chom.2008.09.009
Deshmukh, H. S. et al. The microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis in neonatal mice. Nat. Med. 20, 524–530 (2014).
pubmed: 24747744
pmcid: 4016187
doi: 10.1038/nm.3542
Pamer, E. G. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352, 535–538 (2016).
pubmed: 27126035
pmcid: 4984266
doi: 10.1126/science.aad9382
Freter, R. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of normal enteric flora. J. Infect. Dis. 97, 57–65 (1955). An early study identifying the protection against infection conferred by an intact microbiota.
pubmed: 13242854
doi: 10.1093/infdis/97.1.57
Miller, C. P., Bohnhoff, M. & Rifkind, D. The effect of an antibiotic on the susceptibility of the mouse’s intestinal tract to Salmonella infection. Trans. Am. Clin. Climatol. Assoc. 68, 51–58 (1957).
pmcid: 2248925
Sekirov, I. et al. Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection. Infect. Immun. 76, 4726–4736 (2008).
pubmed: 18678663
pmcid: 2546810
doi: 10.1128/IAI.00319-08
Hensgens, M. P. M., Goorhuis, A., Dekkers, O. M. & Kuijper, E. J. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J. Antimicrob. Chemother. 67, 742–748 (2012). A multicenter case–control study to determine the period at risk for CDI after cessation of antibiotics.
pubmed: 22146873
doi: 10.1093/jac/dkr508
Tvede, M. & Rask-Madsen, J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 333, 1156–1160 (1989).
doi: 10.1016/S0140-6736(89)92749-9
van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
pubmed: 23323867
doi: 10.1056/NEJMoa1205037
Buffie, C. G. et al. Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile. Nature 517, 205–208 (2015). Bile-acid-mediated colonization resistance against C. difficile could be restored by the human gut commensal C. scindens.
pubmed: 25337874
doi: 10.1038/nature13828
Aguirre, A. M. et al. Bile acid-independent protection against Clostridioides difficile infection. PLoS Pathog. 17, e1010015 (2021).
pubmed: 34665847
pmcid: 8555850
doi: 10.1371/journal.ppat.1010015
Gregory, A. L., Pensinger, D. A. & Hryckowian, A. J. A short chain fatty acid-centric view of Clostridioides difficile pathogenesis. PLoS Pathog. 17, e1009959 (2021).
pubmed: 34673840
pmcid: 8530303
doi: 10.1371/journal.ppat.1009959
Iwata, K. et al. A systematic review for pursuing the presence of antibiotic associated enterocolitis caused by methicillin resistant Staphylococcus aureus. BMC Infect. Dis. 14, 247 (2014).
pubmed: 24884581
pmcid: 4025539
doi: 10.1186/1471-2334-14-247
Lane, A. B., Copeland, N. K., Onmus-Leone, F. & Lawler, J. V. Methicillin-resistant Staphylococcus aureus as a probable cause of antibiotic-associated enterocolitis. Case Rep. Infect. Dis. 2018, e3106305 (2018).
Lichtman, J. S. et al. Host–microbiota interactions in the pathogenesis of antibiotic-associated diseases. Cell Rep. 14, 1049–1061 (2016).
pubmed: 26832403
pmcid: 5372703
doi: 10.1016/j.celrep.2016.01.009
Pavia, A. T. et al. Epidemiologic evidence that prior antimicrobial exposure decreases resistance to infection by antimicrobial-sensitive Salmonella. J. Infect. Dis. 161, 255–260 (1990).
pubmed: 2299207
doi: 10.1093/infdis/161.2.255
Holmberg, S. D., Osterholm, M. T., Senger, K. A. & Cohen, M. L. Drug-resistant Salmonella from animals fed antimicrobials. N. Engl. J. Med. 311, 617–622 (1984).
pubmed: 6382001
doi: 10.1056/NEJM198409063111001
Gradel, K. O., Dethlefsen, C., Ejlertsen, T., Schønheyder, H. C. & Nielsen, H. Increased prescription rate of antibiotics prior to non-typhoid Salmonella infections: a one-year nested case–control study. Scand. J. Infect. Dis. 40, 635–641 (2008).
pubmed: 18979601
doi: 10.1080/00365540801961248
Doorduyn, Y., Van Den Brandhof, W. E., Van Duynhoven, Y. T. H. P., Wannet, W. J. B. & Van Pelt, W. Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections. Epidemiol. Infect. 134, 617–626 (2006).
pubmed: 16638166
doi: 10.1017/S0950268805005406
Malik, U. et al. Association between prior antibiotic therapy and subsequent risk of community-acquired infections: a systematic review. J. Antimicrob. Chemother. 73, 287–296 (2018).
pubmed: 29149266
doi: 10.1093/jac/dkx374
Humphreys, H. et al. Four country healthcare associated infection prevalence survey 2006: risk factor analysis. J. Hosp. Infect. 69, 249–257 (2008).
pubmed: 18550214
doi: 10.1016/j.jhin.2008.04.021
Chen, Y. E., Fischbach, M. A. & Belkaid, Y. Skin microbiota–host interactions. Nature 553, 427–436 (2018).
pubmed: 29364286
pmcid: 6075667
doi: 10.1038/nature25177
Nakatsuji, T. et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci. Transl. Med. 9, eaah4680 (2017).
pubmed: 28228596
pmcid: 5600545
doi: 10.1126/scitranslmed.aah4680
Zipperer, A. et al. Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535, 511–516 (2016).
pubmed: 27466123
doi: 10.1038/nature18634
Belkaid, Y. & Segre, J. A. Dialogue between skin microbiota and immunity. Science 346, 954–959 (2014).
pubmed: 25414304
doi: 10.1126/science.1260144
Liu, Q. et al. Staphylococcus epidermidis contributes to healthy maturation of the nasal microbiome by stimulating antimicrobial peptide production. Cell Host Microbe 27, 68–78.e5 (2020).
pubmed: 31866425
doi: 10.1016/j.chom.2019.11.003
Man, W. H., de Steenhuijsen Piters, W. A. A. & Bogaert, D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat. Rev. Microbiol. 15, 259–270 (2017).
pubmed: 28316330
pmcid: 7097736
doi: 10.1038/nrmicro.2017.14
Clark, S. E. Commensal bacteria in the upper respiratory tract regulate susceptibility to infection. Curr. Opin. Immunol. 66, 42–49 (2020).
pubmed: 32416468
pmcid: 7665980
doi: 10.1016/j.coi.2020.03.010
Santagati, M., Scillato, M., Patanè, F., Aiello, C. & Stefani, S. Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. FEMS Immunol. Med. Microbiol. 65, 23–31 (2012).
pubmed: 22243526
doi: 10.1111/j.1574-695X.2012.00928.x
Horn, K. J. et al. Corynebacterium species inhibit Streptococcus pneumoniae colonization and infection of the mouse airway. Front. Microbiol. 12, 804935 (2021).
pubmed: 35082772
doi: 10.3389/fmicb.2021.804935
Thackray, L. B. et al. Oral antibiotic treatment of mice exacerbates the disease severity of multiple flavivirus infections. Cell Rep. 22, 3440–3453.e6 (2018).
pubmed: 29590614
pmcid: 5908250
doi: 10.1016/j.celrep.2018.03.001
Margolis, D. J., Bowe, W. P., Hoffstad, O. & Berlin, J. A. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch. Dermatol. 141, 1132–1136 (2005).
pubmed: 16172310
doi: 10.1001/archderm.141.9.1132
Smith, H. S. et al. Antecedent antimicrobial use increases the risk of uncomplicated cystitis in young women. Clin. Infect. Dis. 25, 63–68 (1997).
pubmed: 9243034
doi: 10.1086/514502
Robinson, C. J. & Young, V. B. Antibiotic administration alters the community structure of the gastrointestinal micobiota. Gut Microbes 1, 279–284 (2010).
pubmed: 20953272
pmcid: 2954510
doi: 10.4161/gmic.1.4.12614
Zacharioudakis, I. M., Zervou, F. N., Pliakos, E. E., Ziakas, P. D. & Mylonakis, E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am. J. Gastroenterol. 110, 381–390 (2015).
pubmed: 25732416
doi: 10.1038/ajg.2015.22
Stevens, E. J., Bates, K. A. & King, K. C. Host microbiota can facilitate pathogen infection. PLoS Pathog. 17, e1009514 (2021).
pubmed: 33984069
pmcid: 8118302
doi: 10.1371/journal.ppat.1009514
Kluytmans-van den Bergh, M. F. Q. et al. Rectal carriage of extended-spectrum-β-lactamase-producing enterobacteriaceae in hospitalized patients: selective preenrichment increases yield of screening. J. Clin. Microbiol. 53, 2709–2712 (2015).
pubmed: 25994164
pmcid: 4508429
doi: 10.1128/JCM.01251-15
Sheppard, S. K. Strain wars and the evolution of opportunistic pathogens. Curr. Opin. Microbiol. 67, 102138 (2022).
pubmed: 35168173
doi: 10.1016/j.mib.2022.01.009
Donskey, C. J. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin. Infect. Dis. 39, 219–226 (2004).
pubmed: 15307031
doi: 10.1086/422002
Sim, C. K. et al. A mouse model of occult intestinal colonization demonstrating antibiotic-induced outgrowth of carbapenem-resistant Enterobacteriaceae. Microbiome 10, 43 (2022). Mice colonized with resistant bacteria at undetectable levels showed overgrowth following antibiotic treatment.
pubmed: 35272717
pmcid: 8908617
doi: 10.1186/s40168-021-01207-6
Maurice, C. F., Haiser, H. J. & Turnbaugh, P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152, 39–50 (2013).
pubmed: 23332745
pmcid: 3552296
doi: 10.1016/j.cell.2012.10.052
Bottery, M. J. et al. Inter-species interactions alter antibiotic efficacy in bacterial communities. ISME J. 16, 812–821 (2022).
pubmed: 34628478
doi: 10.1038/s41396-021-01130-6
Tavernier, S. et al. Community composition determines activity of antibiotics against multispecies biofilms. Antimicrob. Agents Chemother. 61, e00302–e00317 (2017).
pubmed: 28696232
pmcid: 5571329
doi: 10.1128/AAC.00302-17
Brown, G. D. et al. Hidden killers: human fungal infections. Sci. Transl. Med. 4, 165rv13 (2012).
pubmed: 23253612
doi: 10.1126/scitranslmed.3004404
Mayer, F. L., Wilson, D. & Hube, B. Candida albicans pathogenicity mechanisms. Virulence 4, 119–128 (2013).
pubmed: 23302789
pmcid: 3654610
doi: 10.4161/viru.22913
Xu, J. et al. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J. Am. Board. Fam. Med. 21, 261–268 (2008).
pubmed: 18612052
doi: 10.3122/jabfm.2008.04.070169
MacDonald, T. M. et al. The risks of symptomatic vaginal candidiasis after oral antibiotic therapy. Q. J. Med. 86, 419–424 (1993).
pubmed: 8210296
Tan, C. T., Xu, X., Qiao, Y. & Wang, Y. A peptidoglycan storm caused by β-lactam antibiotic’s action on host microbiota drives Candida albicans infection. Nat. Commun. 12, 2560 (2021).
pubmed: 33963193
pmcid: 8105390
doi: 10.1038/s41467-021-22845-2
Seelig, M. S. The role of antibiotics in the pathogenesis of Candida infections. Am. J. Med. 40, 887–917 (1966).
pubmed: 5327890
doi: 10.1016/0002-9343(66)90204-X
Takahashi, S. et al. Septic pulmonary embolism caused by Candida albicans after treatment for urinary multidrug-resistant Pseudomonas aeruginosa. J. Infect. Chemother. 14, 436–438 (2008).
pubmed: 19089558
doi: 10.1007/s10156-008-0646-8
Zhai, B. et al. High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis. Nat. Med. 26, 59–64 (2020).
pubmed: 31907459
pmcid: 7005909
doi: 10.1038/s41591-019-0709-7
Samonis, G. et al. Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans. Antimicrob. Agents Chemother. 37, 51–53 (1993).
pubmed: 8431017
pmcid: 187603
doi: 10.1128/AAC.37.1.51
Spigaglia, P., Mastrantonio, P. & Barbanti, F. in Updates on Clostridium difficile in Europe: Advances in Microbiology, Infectious Diseases and Public Health Volume 8 (eds Mastrantonio, P. & Rupnik, M.) 137–159 (Springer International, 2018). https://doi.org/10.1007/978-3-319-72799-8_9 .
Toth, M., Stewart, N. K., Smith, C. & Vakulenko, S. B. Intrinsic class D β-lactamases of Clostridium difficile. mBio 9, e01803–e01818 (2018).
pubmed: 30563905
pmcid: 6299217
doi: 10.1128/mBio.01803-18
Eyre, D. W. et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N. Engl. J. Med. 369, 1195–1205 (2013). A study showing that many C. difficile infections are not the result of transmission chains in hospital settings.
pubmed: 24066741
doi: 10.1056/NEJMoa1216064
Ayres, J. S., Trinidad, N. J. & Vance, R. E. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the microbiota. Nat. Med. 18, 799–806 (2012).
pubmed: 22522562
pmcid: 3472005
doi: 10.1038/nm.2729
Segura Munoz, R. R. et al. Experimental evaluation of ecological principles to understand and modulate the outcome of bacterial strain competition in gut microbiomes. ISME J. 16, 1594–1604 (2022).
pubmed: 35210551
pmcid: 9122919
doi: 10.1038/s41396-022-01208-9
Hardin, G. The competitive exclusion principle. Science 131, 1292–1297 (1960).
pubmed: 14399717
doi: 10.1126/science.131.3409.1292
Lentsch, V. et al. Combined oral vaccination with niche competition can generate sterilizing immunity against enteropathogenic bacteria. Preprint at bioRxiv https://doi.org/10.1101/2022.07.20.498444 (2022).
Lee, S. M. et al. Bacterial colonization factors control specificity and stability of the gut microbiota. Nature 501, 426–429 (2013).
pubmed: 23955152
pmcid: 3893107
doi: 10.1038/nature12447
Murray, B. E., Rensimer, E. R. & Dupont, H. L. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim–sulfamethoxazole. N. Engl. J. Med. 306, 130–135 (1982).
pubmed: 7033781
doi: 10.1056/NEJM198201213060302
Palleja, A. et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat. Microbiol. 3, 1255–1265 (2018).
pubmed: 30349083
doi: 10.1038/s41564-018-0257-9
Vollaard, E. J., Clasener, H. A. L., van Griethuysen, A. J. A., Janssen, A. J. & Sanders-Reijmers, A. J. Influence of amoxycillin, erythromycin and roxithromycin on colonization resistance and on appearance of secondary colonization in healthy volunteers. J. Antimicrob. Chemother. 20, 131–138 (1987).
pubmed: 3429382
doi: 10.1093/jac/20.suppl_B.131
Brandl, K. et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 455, 804–807 (2008).
pubmed: 18724361
pmcid: 2663337
doi: 10.1038/nature07250
Ubeda, C. et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J. Clin. Invest. 120, 4332–4341 (2010). This study showed how VRE overgrow in the intestine during antibiotic treatment.
pubmed: 21099116
pmcid: 2993598
doi: 10.1172/JCI43918
Soares, F. S. et al. Antibiotic-induced pathobiont dissemination accelerates mortality in severe experimental pancreatitis. Front. Immunol. 8, 1890 (2017).
pubmed: 29375557
pmcid: 5770733
doi: 10.3389/fimmu.2017.01890
Drummond, R. A. et al. Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria. Cell Host Microbe 30, 1020–1033.e6 (2022).
pubmed: 35568028
pmcid: 9283303
doi: 10.1016/j.chom.2022.04.013
Knoop, K. A., McDonald, K. G., Kulkarni, D. H. & Newberry, R. D. Antibiotics promote inflammation through the translocation of native commensal colonic bacteria. Gut 65, 1100–1109 (2016).
pubmed: 26045138
doi: 10.1136/gutjnl-2014-309059
Forde, B. M. et al. Population dynamics of an Escherichia coli ST131 lineage during recurrent urinary tract infection. Nat. Commun. 10, 3643 (2019).
pubmed: 31409795
pmcid: 6692316
doi: 10.1038/s41467-019-11571-5
Flores-Mireles, A. L., Walker, J. N., Caparon, M. & Hultgren, S. J. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol. 13, 269–284 (2015).
pubmed: 25853778
pmcid: 4457377
doi: 10.1038/nrmicro3432
Wheatley, R. M. et al. Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient. Nat. Commun. 13, 6523 (2022).
pubmed: 36414617
pmcid: 9681761
doi: 10.1038/s41467-022-34101-2
Lawley, T. D. et al. Antibiotic treatment of Clostridium difficile carrier mice triggers a supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts. Infect. Immun. 77, 3661–3669 (2009).
pubmed: 19564382
pmcid: 2737984
doi: 10.1128/IAI.00558-09
Magill, S. S. et al. Prevalence of antimicrobial use in US acute care hospitals, May–September 2011. J. Am. Med. Asssoc. 312, 1438–1446 (2014).
doi: 10.1001/jama.2014.12923
Stracy, M. et al. Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections. Science 375, 889–894 (2022). Personalized antibiotic recommendations could reduce the emergence of resistance during antibiotic treatment.
pubmed: 35201862
pmcid: 7612469
doi: 10.1126/science.abg9868
Caballero, J. D. et al. Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients. Nat. Commun. 14, 4083 (2023).
doi: 10.1038/s41467-023-39416-2
Tchesnokova, V. L. et al. Pandemic uropathogenic fluoroquinolone-resistant Escherichia coli have enhanced ability to persist in the gut and cause bacteriuria in healthy women. Clin. Infect. Dis. 70, 937–939 (2020).
pubmed: 31271206
doi: 10.1093/cid/ciz547
von Eiff, C., Becker, K., Machka, K., Stammer, H. & Peters, G. Nasal carriage as a source of Staphylococcus aureus bacteremia. N. Engl. J. Med. 344, 11–16 (2001).
doi: 10.1056/NEJM200101043440102
Gasparrini, A. J. et al. Persistent metagenomic signatures of early-life hospitalization and antibiotic treatment in the infant gut microbiota and resistome. Nat. Microbiol. 4, 2285–2297 (2019).
pubmed: 31501537
pmcid: 6879825
doi: 10.1038/s41564-019-0550-2
Korpela, K. et al. Intestinal microbiome is related to lifetime antibiotic use in Finnish pre-school children. Nat. Commun. 7, 10410 (2016).
pubmed: 26811868
pmcid: 4737757
doi: 10.1038/ncomms10410
Jernberg, C., Löfmark, S., Edlund, C. & Jansson, J. K. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiol. Read. Engl. 156, 3216–3223 (2010).
doi: 10.1099/mic.0.040618-0
Wenzler, E., Mulugeta, S. G. & Danziger, L. H. The antimicrobial stewardship approach to combating Clostridium difficile. Antibiotics 4, 198–215 (2015).
pubmed: 27025621
pmcid: 4790327
doi: 10.3390/antibiotics4020198
Baur, D. et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect. Dis. 17, 990–1001 (2017).
pubmed: 28629876
doi: 10.1016/S1473-3099(17)30325-0
Aldeyab, M. A. et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J. Antimicrob. Chemother. 67, 2988–2996 (2012).
pubmed: 22899806
doi: 10.1093/jac/dks330
Wiesch, P. A., zur, Kouyos, R., Abel, S., Viechtbauer, W. & Bonhoeffer, S. Cycling empirical antibiotic therapy in hospitals: meta-analysis and models. PLoS Pathog. 10, e1004225 (2014).
doi: 10.1371/journal.ppat.1004225
Moser, C. et al. Antibiotic therapy as personalized medicine — general considerations and complicating factors. APMIS 127, 361–371 (2019).
pubmed: 30983040
doi: 10.1111/apm.12951
Yeh, Y.-C., Huang, T.-H., Yang, S.-C., Chen, C.-C. & Fang, J.-Y. Nano-based drug delivery or targeting to eradicate bacteria for infection mitigation: a review of recent advances. Front. Chem. 8, 286 (2020).
pubmed: 32391321
pmcid: 7193053
doi: 10.3389/fchem.2020.00286
Wang, Y. et al. Targeted delivery of antibiotics to the infected pulmonary tissues using ROS-responsive nanoparticles. J. Nanobiotechnol. 17, 103 (2019).
doi: 10.1186/s12951-019-0537-4
Yao, J. et al. A pathogen-selective antibiotic minimizes disturbance to the microbiome. Antimicrob. Agents Chemother. 60, 4264–4273 (2016).
pubmed: 27161626
pmcid: 4914625
doi: 10.1128/AAC.00535-16
Mu, H. et al. Pathogen-targeting glycovesicles as a therapy for salmonellosis. Nat. Commun. 10, 4039 (2019).
pubmed: 31492864
pmcid: 6731243
doi: 10.1038/s41467-019-12066-z
Brochado, A. R. et al. Species-specific activity of antibacterial drug combinations. Nature 559, 259–263 (2018).
pubmed: 29973719
pmcid: 6219701
doi: 10.1038/s41586-018-0278-9
Gutiérrez, B. & Domingo-Calap, P. Phage therapy in gastrointestinal diseases. Microorganisms 8, 1420 (2020).
pubmed: 32947790
pmcid: 7565598
doi: 10.3390/microorganisms8091420
Cotter, P. D., Ross, R. P. & Hill, C. Bacteriocins — a viable alternative to antibiotics? Nat. Rev. Microbiol. 11, 95–105 (2013).
pubmed: 23268227
doi: 10.1038/nrmicro2937
Meade, E., Slattery, M. A. & Garvey, M. Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: resistance is futile? Antibiotics 9, 32 (2020).
pubmed: 31963311
pmcid: 7168330
doi: 10.3390/antibiotics9010032
Hatfull, G. F., Dedrick, R. M. & Schooley, R. T. Phage therapy for antibiotic-resistant bacterial infections. Annu. Rev. Med. 73, 197–211 (2022).
pubmed: 34428079
doi: 10.1146/annurev-med-080219-122208
Dedrick, R. M. et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med. 25, 730–733 (2019).
pubmed: 31068712
pmcid: 6557439
doi: 10.1038/s41591-019-0437-z
Schooley, R. T. et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob. Agents Chemother. 61, e00954-17 (2017).
pubmed: 28807909
pmcid: 5610518
doi: 10.1128/AAC.00954-17
Rea, M. C. et al. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl Acad. Sci. USA 107, 9352–9357 (2010).
pubmed: 20435915
pmcid: 2889069
doi: 10.1073/pnas.0913554107
McDonald, L. C. et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66, 987–994 (2018).
pubmed: 29562266
doi: 10.1093/cid/ciy149
Yelin, I. et al. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat. Med. 25, 1728–1732 (2019).
pubmed: 31700189
pmcid: 6980696
doi: 10.1038/s41591-019-0626-9
Suez, J. et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell 174, 1406–1423.e16 (2018).
pubmed: 30193113
doi: 10.1016/j.cell.2018.08.047
Imperial, I. C. V. J. & Ibana, J. A. Addressing the antibiotic resistance problem with probiotics: reducing the risk of its double-edged sword effect. Front. Microbiol. 7, 1983 (2016).
pubmed: 28018315
pmcid: 5156686
doi: 10.3389/fmicb.2016.01983
Kassam, Z., Lee, C. H., Yuan, Y. & Hunt, R. H. Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis. Am. J. Gastroenterol. 108, 500 (2013).
pubmed: 23511459
doi: 10.1038/ajg.2013.59
Pamer, E. G. Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns. Mucosal Immunol. 7, 210–214 (2014).
pubmed: 24399149
doi: 10.1038/mi.2013.117
Taur, Y. et al. Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. Sci. Transl. Med. 10, eaap9489 (2018).
pubmed: 30257956
pmcid: 6468978
doi: 10.1126/scitranslmed.aap9489
DeFilipp, Z. et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant. N. Engl. J. Med. 381, 2043–2050 (2019).
pubmed: 31665575
doi: 10.1056/NEJMoa1910437
Amrane, S. & Lagier, J.-C. Fecal microbiota transplantation for antibiotic resistant bacteria decolonization. Hum. Microbiome J. 16, 100071 (2020). A comprehensive overview of the application of FMT to decolonize the gut of antibiotic resistance bacteria.
doi: 10.1016/j.humic.2020.100071
Walker, A. W. et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 5, 220–230 (2011).
pubmed: 20686513
doi: 10.1038/ismej.2010.118
Stecher, B. & Hardt, W.-D. Mechanisms controlling pathogen colonization of the gut. Curr. Opin. Microbiol. 14, 82–91 (2011).
pubmed: 21036098
doi: 10.1016/j.mib.2010.10.003
Pickard, J. M. & Núñez, G. Pathogen colonization resistance in the gut and its manipulation for improved health. Am. J. Pathol. 189, 1300–1310 (2019).
pubmed: 31100210
pmcid: 6617533
doi: 10.1016/j.ajpath.2019.03.003
Russell, A. B., Peterson, S. B. & Mougous, J. D. Type VI secretion system effectors: poisons with a purpose. Nat. Rev. Microbiol. 12, 137–148 (2014).
pubmed: 24384601
pmcid: 4256078
doi: 10.1038/nrmicro3185
Brunet, Y. R., Espinosa, L., Harchouni, S., Mignot, T. & Cascales, E. Imaging type VI secretion-mediated bacterial killing. Cell Rep. 3, 36–41 (2013).
pubmed: 23291094
doi: 10.1016/j.celrep.2012.11.027
Cotter, P. D., Hill, C. & Ross, R. P. Bacteriocins: developing innate immunity for food. Nat. Rev. Microbiol. 3, 777–788 (2005).
pubmed: 16205711
doi: 10.1038/nrmicro1273
Vital, M., Rud, T., Rath, S., Pieper, D. H. & Schlüter, D. Diversity of bacteria exhibiting bile acid-inducible 7α-dehydroxylation genes in the human gut. Comput. Struct. Biotechnol. J. 17, 1016–1019 (2019).
pubmed: 31428294
pmcid: 6692061
doi: 10.1016/j.csbj.2019.07.012
Didelot, X., Walker, A. S., Peto, T. E., Crook, D. W. & Wilson, D. J. Within-host evolution of bacterial pathogens. Nat. Rev. Microbiol. 14, 150–162 (2016).
pubmed: 26806595
pmcid: 5053366
doi: 10.1038/nrmicro.2015.13
Ikuta, K. S. et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400, 2221–2248 (2022).
doi: 10.1016/S0140-6736(22)02185-7
Magruder, M. et al. Gut uropathogen abundance is a risk factor for development of bacteriuria and urinary tract infection. Nat. Commun. 10, 5521 (2019).
pubmed: 31797927
pmcid: 6893017
doi: 10.1038/s41467-019-13467-w